APA (7th ed.) Citation

Pariser, D. M., Lebwohl, M. G., Jaworski, J., Trefler, J., Daniluk, S., Dudek, A., . . . Koo, J. Y. (2025). CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study. Dermatology and therapy, 15(5), 1079-1092. https://doi.org/10.1007/s13555-025-01383-5

Chicago Style (17th ed.) Citation

Pariser, David M., et al. "CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study." Dermatology and Therapy 15, no. 5 (2025): 1079-1092. https://doi.org/10.1007/s13555-025-01383-5.

MLA (9th ed.) Citation

Pariser, David M., et al. "CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study." Dermatology and Therapy, vol. 15, no. 5, 2025, pp. 1079-1092, https://doi.org/10.1007/s13555-025-01383-5.